Consortium Building
Lead Research Organisation:
University of Manchester
Department Name: Medical and Human Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
- University of Manchester (Lead Research Organisation)
- Novartis (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- Newcastle University (Collaboration)
- QIAGEN (Collaboration)
- Sanquin (Collaboration)
- British Association of Dermatologists (BAD) (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- AstraZeneca (Collaboration)
- AbbVie Inc (Collaboration)
- Becton, Dickinson and Company (Collaboration)
- Pfizer Ltd (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Guy's and St Thomas' NHS Foundation Trust (Collaboration)
- Johnson & Johnson (Collaboration)
- LEO Pharma (Collaboration)
- Royal College of Physicians of London (Collaboration)
- The Psoriasis Association (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
People |
ORCID iD |
Christopher Griffiths (Principal Investigator) |
Description | MRC Stratified Medicine Consortium Awards |
Amount | £4,900,000 (GBP) |
Funding ID | MR/L011808/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2014 |
End | 08/2018 |
Description | PSORT |
Organisation | AbbVie Inc |
Country | United States |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | AstraZeneca |
Department | MedImmune |
Country | United Kingdom |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Becton, Dickinson and Company |
Country | United States |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Bristol-Myers Squibb |
Department | Celgene |
Country | United States |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | British Association of Dermatologists (BAD) |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Eli Lilly & Company Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | GlaxoSmithKline (GSK) |
Department | Steifel |
Country | United States |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Guy's and St Thomas' NHS Foundation Trust |
Department | Dermatology |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Johnson & Johnson |
Department | Janssen-Cilag |
Country | Global |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | LEO Pharma |
Country | Ireland |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
Country | United Kingdom |
Sector | Public |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Newcastle University |
Department | Dermatological Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Novartis |
Country | Global |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Pfizer Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | QIAGEN |
Department | QIAGEN (Netherlands) |
Country | Netherlands |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Queen Mary University of London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Royal College of Physicians of London |
Country | United Kingdom |
Sector | Learned Society |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Royal College of Physicians of London |
Country | United Kingdom |
Sector | Learned Society |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | Sanquin |
Country | Netherlands |
Sector | Private |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | The Psoriasis Association |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |
Description | PSORT |
Organisation | University of Liverpool |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. |
Collaborator Contribution | The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions. |
Impact | Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance |
Start Year | 2014 |